Mode
Text Size
Log in / Sign up

Decision support tools lower inappropriate antibiotic use in UK adultsDecision Support Tools May Reduce Inappropriate Antibiotic Use

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider decision support tools to reduce inappropriate antibiotic use, but effect is small and from a simulated setting.

In a pre-registered online experiment, 663 UK adults were randomized to receive a decision support leaflet (WHO) alone or in combination with a value integration task, active symptom monitoring, or both, compared with a control condition. The primary outcome was inappropriate antibiotic use, measured in a behavioral game with financial incentives. Secondary outcomes included decisional conflict, value clarity, and perceived decisional support.

All decision support conditions led to lower inappropriate antibiotic use compared with control (p <.001, eta = 0.02). Decisional conflict was also reduced by the decision support tools (p <.001, eta = 0.02). Absolute numbers were not reported. The effect sizes were small, indicating modest differences.

Safety data were not reported. The study did not assess adverse events, serious adverse events, or discontinuations. Tolerability was not reported.

Key limitations include the use of a behavioral game measure with behavior-contingent financial incentives to model real-world scenarios, which may not fully reflect clinical practice. The study was conducted online, and follow-up duration was not reported.

For clinicians, integrating decision support tools into delayed prescription procedures may contribute to a more informed and responsible approach to antibiotic use. However, these findings are preliminary and based on a simulated setting; real-world effectiveness remains to be confirmed.

How this fits prior evidence

This randomized experiment extends prior coverage by addressing a gap in behavioral interventions for antibiotic stewardship. While earlier systematic reviews focused on antiviral strategies and cfDNA analysis, this study provides direct evidence that decision support tools can reduce inappropriate antibiotic use in a simulated setting. The small effect size (eta = 0.02) suggests a modest benefit, consistent with the cautious tone of prior coverage on experimental interventions. The findings are preliminary and require validation in clinical settings.

A study involving 663 adults in the UK looked at how different types of information affect decisions about antibiotic use. Researchers tested whether providing a decision support leaflet from the World Health Organization, combined with other tasks like active symptom monitoring or value integration, could help people decide correctly when they have a viral infection.

The results showed that all groups receiving some form of decision support had lower rates of inappropriate antibiotic use compared to the control group. These tools also helped participants feel less conflicted about their choices and gave them more clarity on their personal values regarding treatment.

It is important to note that this study used a behavioral game with financial incentives to simulate real-world situations rather than actual clinical practice. While the results are promising for improving how people handle common infections, the findings come from a simulated environment. You should always speak with your doctor to determine the best treatment for your specific health needs.

What this means for you:
Decision support tools may help people make more informed choices about using antibiotics for viral infections.

Common questions

Can these tools help people decide if they need antibiotics?

Yes, the study found that providing a decision support leaflet from the World Health Organization helped reduce inappropriate antibiotic use. These tools also reduced decisional conflict and improved value clarity for the 663 adults who participated in the trial.

What kind of interventions were tested?

The study tested a decision support leaflet alone or combined with other tasks, such as active symptom monitoring and value integration. All conditions that included these tools showed lower rates of inappropriate antibiotic use compared to the control group.

Is this finding based on real-world doctor visits?

The study used a behavioral game with financial incentives to model real-world scenarios rather than actual clinical practice. Because it was a simulated environment, you should still consult your healthcare provider for medical advice.

Study Details

Study typeRct
EvidenceLevel 2
PublishedAug 2026
View Original Abstract ↓
Antimicrobial resistance is partly driven by overprescribing antibiotics in primary care. Delayed antibiotic prescriptions, which allow patients to monitor their symptoms before deciding to use antibiotics, are a promising intervention. However, this strategy is undermined when patients initiate antibiotic use immediately. Using a behavioural game measure with behaviour-contingent financial incentives that models delayed prescriptions, we examined whether a decision support leaflet issued by the World Health Organization can, alone or in combination with other evidence-based interventions, reduce inappropriate antibiotic use for viral infections. In a pre-registered online experiment (N = 663 UK adults), participants were randomly assigned to one of five experimental conditions: (i) control condition, (ii) leaflet only, (iii) leaflet with value integration task, (iv) leaflet with active symptom monitoring and (v) leaflet with value integration and active monitoring. Inappropriate antibiotic use was lower in all decision support conditions than in the control condition (p < .001, η  = .02). Decision support tools also reduced decisional conflict (p < .001, η  = .02), particularly by improving value clarity and perceived decisional support. Integrating decision support tools into delayed prescription procedures can contribute to a more informed and responsible approach to antibiotic use by providing relevant information and tools.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.